Accutar Biotech

Overview: AccutarBio employs artificial intelligence to revolutionize drug discovery. With capabilities in side chain flexible mode ligand docking, virtual screening, and drug ADME property prediction, Accutar’s platform beats the industry standard in computation-aided drug design. The company’s hybrid based approach, which uses computational drug design followed by wet lab validation, greatly reduces the time and cost necessary for traditional drug discovery efforts. Accutar is committed to bui[1][2]

Visit website Suggest an update

2015 Founded1 Person on the graph

Overview

Accutar Biotech is a New York City-based artificial intelligence company in the healthcare sector [1]. The company employs artificial intelligence in drug discovery, with capabilities including side chain flexible mode ligand docking, virtual screening, and drug ADME property prediction [2]. Accutar's platform operates through a hybrid approach combining computational drug design with wet lab validation [2]. According to company information, this methodology reduces the time and cost requirements of traditional drug discovery efforts [2]. The company has 37 employees and operates in the biotechnology research industry [3].

Business address: 760 Parkside Ave, New York, New York, 11226. [5]

Growth & traction

LinkedIn lists 37 people working at Accutar Biotech. [4]

Key people

Wenjun X.Head of BD&L

Something wrong or missing? Send an update. Fixed within 24 hours.